Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eterna Therapeutics Inc.

2.45
-0.1800-6.84%
Post-market: 2.650.2000+8.16%19:25 EDT
Volume:38.34K
Turnover:97.85K
Market Cap:18.03M
PE:-0.05
High:2.64
Open:2.64
Low:2.45
Close:2.63
Loading ...

Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split

MT Newswires Live
·
13 Jun

Charles Cherington, 10% Owner, Reports Acquisition of Common Shares in Ernexa Therapeutics Inc

Reuters
·
12 Jun

Eterna Therapeutics Files for Resale of 57 Million Shares

MT Newswires Live
·
12 Jun

Ernexa Therapeutics files to sell 57.05M shares of common stock for holders

TIPRANKS
·
12 Jun

Ernexa Therapeutics announces 1-for-15 reverse stock split

TIPRANKS
·
10 Jun

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
10 Jun

Ernexa Therapeutics Inc. Completes Second Closing of Private Placement, Issuing 57.65 Million Shares and Raising $7 Million

Reuters
·
10 Jun

Ernexa Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
03 Jun

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of Erna-101 and Future Clinical Operations

THOMSON REUTERS
·
14 May

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

GlobeNewswire
·
29 Apr

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

GlobeNewswire
·
22 Apr

Ernexa Therapeutics Closes New Funding Round

GlobeNewswire
·
03 Apr

Eterna appoints Zeldis, Sather to scientific advisory board

TIPRANKS
·
28 Jan

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

THOMSON REUTERS
·
28 Jan

Press Release: Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Dow Jones
·
28 Jan

Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump

MT Newswires Live
·
14 Jan

Eterna announces preclinical study results on ERNA-101

TIPRANKS
·
14 Jan

Eterna Therapeutics Inc - Erna-101 Expected to Enhance Efficacy of CAR-T and Car-Nk Therapies

THOMSON REUTERS
·
14 Jan

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product Erna-101 in Ovarian Cancer

THOMSON REUTERS
·
14 Jan

Eterna Therapeutics Inc - Erna-101 Treated Mice Show Significant Survival Advantage

THOMSON REUTERS
·
14 Jan